Antiangiogenic Therapy Efficacy Can Be Tumor-Size Dependent, as Mathematical Modeling Suggests

Abstract

Antiangiogenic therapy (AAT) is an indirect oncological modality that is aimed at the disruption of cancer cell nutrient supply. Invasive tumors have been shown to possess inherent resistance to this treatment, while compactly growing benign tumors react to it by shrinking. It is generally accepted that AAT by itself is not curative. This study presents a mathematical model of non-invasive tumor growth with a physiologically justified account of microvasculature alteration and the biomechanical aspects of importance during tumor growth and AAT. In the untreated setting, the model reproduces tumor growth with saturation, where the maximum tumor volume depends on the level of angiogenesis. The outcomes of the AAT simulations depend on the tumor size at the moment of treatment initiation. If it is close to the stable size of an avascular tumor grown in the absence of angiogenesis, then the tumor is rapidly stabilized by AAT. The treatment of large tumors is accompanied by the displacement of normal tissue due to tumor shrinkage. During this, microvasculature undergoes distortion, the degree of which depends on the displacement distance. As it affects tumor nutrient supply, the stable size of a tumor that undergoes AAT negatively correlates with its size at the beginning of treatment. For sufficiently large initial tumors, the long-term survival of tumor cells is compromised by competition with normal cells for the severely limited inflow of nutrients, which makes AAT effectively curative.